In February 2026, the U.S. Food and Drug Administration approved important labeling changes to the first group of menopausal hormone therapy products. This decision reflects a growing recognition that menopause care deserves updated, evidence based communication that aligns with current science rather than outdated fear.
For decades, many hormone therapy products carried a boxed warning highlighting risks such as cardiovascular disease, breast cancer, and probable dementia. These warnings were largely based on early interpretations of data from the Women’s Health Initiative in the early 2000s. While that research was valuable, subsequent analysis has clarified that risk varies significantly depending on timing, age, formulation, and individual health history.
What Changed
In this first round of updates, the FDA approved removal of certain risk statements from the boxed warnings of six products:
- Prometrium
- Divigel
- Cenestin
- Enjuvia
- Estring
- Bijuva
This does not mean hormone therapy is risk free. It means the way risk is communicated is being recalibrated to better reflect modern evidence.
Current data show that when hormone therapy is initiated in women under age sixty or within ten years of menopause onset, the benefit risk profile is often favorable for healthy women. Outcomes differ based on route of administration, dose, whether progesterone is required, and individual cardiovascular and cancer risk factors.
Why This Matters
For years, the presence of a boxed warning created significant fear for both patients and clinicians. Hormone therapy use declined sharply after the initial Women’s Health Initiative publication, and many women who could have safely benefited from treatment avoided it altogether.
This labeling update represents more than a regulatory change. It represents a cultural shift in how we view menopause care. It acknowledges nuance. It supports shared decision making. And it allows practitioners to counsel patients without the shadow of language that may no longer accurately represent individualized risk.
My Personal Perspective
By Dr. Mia Chorney
As a practitioner who works closely with women in midlife, I have seen firsthand how fear has shaped menopause care. I have met women who suffered for years with severe hot flashes, sleep disruption, bone loss, and cognitive decline because they believed hormone therapy was inherently dangerous.
In my clinical experience, hormone therapy is neither a miracle nor a menace. It is a powerful medical tool. When prescribed thoughtfully, with careful screening and individualized assessment, it can dramatically improve quality of life and long term health outcomes for the right patient.
This FDA decision validates what many menopause specialists have understood for years. The conversation must move beyond blanket warnings and toward precision medicine. The real question is not whether hormone therapy is good or bad. The real question is who benefits, under what conditions, and how we optimize safety.
I believe this is a pivotal moment in women’s health. It is an opportunity to correct decades of misunderstanding and to empower women with clear, balanced information.
What Women Should Do Now
If you are navigating perimenopause or menopause, this is the time to have an informed conversation with your practitioner. Discuss your symptoms, cardiovascular history, family cancer history, bone density, and overall health goals.
Menopause is not a brief transition. It is a decades-long phase of life. Treatment decisions should reflect that reality.
The FDA update does not eliminate risk. It restores perspective. And perspective is exactly what women deserve.
Dr. Mia Chorney, DNP, FNPBC, MSCP
Co-Founder & Chief Medical Officer~The Pause Technologies Inc.
Scientific Advisory Board Member~Isagenix
Women’s Cardiovascular Health, Cardiovascular Genetics and Precision Medicine